Annual Earnings Preannouncement for 2024
Filed with SSE · · 2 pages · Chinese
Earlier from InnoCare Pharma
- Indicative Announcement on the Postponement of By-election for Independent Non-executive Director
- Announcement on the First Granting of Restricted Stocks to Incentive Objects
- Notice on the Review Opinions and Remarks on Publicity of Lis of Incentive Recipients List for the Initial Grant of the 2024 SSE STAR Market Restricted Stock Incentive Plan
- Notice on Convening the 1st Extraordinary General Meeting (Shareholders' Special Meeting) in 2024
- Summary Announcement on the 2024 STAR Market Restricted Stock Incentive Plan (Draft)
Later from InnoCare Pharma
- Announcement on Signing License Agreement for CD20*CD3 Bispecific Antibody (ICP-B02/CM355) between Subsidiary and Prolium
- Announcement on Appointment of Independent Non-executive Director
- InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China
- Data of InnoCare's Orelabrutinib for the Treatment of MS Released at 2025 ACTRIMS Forum
- Data of InnoCare's ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD
Follow InnoCare Pharma into a list and get an email when it puts out news.
Follow InnoCare Pharma